Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
详细信息 查看全文
- 作者：Antonella Manca (1)
Amelia Lissia (2)
Mariaelena Capone (3)
Paolo A Ascierto (3)
Gerardo Botti (3)
Corrado Carac貌 (3)
Ignazio Stanganelli (4)
Maria Colombino (1)
MariaCristina Sini (1)
Antonio Cossu (2)
Giuseppe Palmieri (1)
1. Institute of Biomolecular Chemistry ; National Research Council (CNR) ; Traversa La Crucca 3 - Baldinca Li Punti ; 07100 ; Sassari ; Italy
2. Department of Pathology ; Hospital-University Health Unit (AOU) ; Sassari ; Italy
3. Istituto Nazionale Tumori ; Fondazione Pascale ; Naples ; Italy
4. Skin Cancer Unit ; Istituto Scientifico Romagnolo Tumori (IRST) ; Meldola ; Italy - 关键词：Melanoma ; Mutation analysis ; PIK3CA gene ; Resistance to BRAF/MEK inhibitors
- 刊名：Journal of Translational Medicine
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：13
- 期：1
- 全文大小：456 KB
- 参考文献：1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949鈥?4. 38/nature00766" target="_blank" title="It opens in new window">CrossRef
2. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135鈥?7. CrossRef
3. Palmieri G, Capone ME, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, et al. Main roads to melanoma. J Transl Med. 2009;7:86. CrossRef
4. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011;6:e22769. 371/journal.pone.0022769" target="_blank" title="It opens in new window">CrossRef
5. Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, et al. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One. 2012;7:e43369. 371/journal.pone.0043369" target="_blank" title="It opens in new window">CrossRef
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489鈥?01. 38/nrc839" target="_blank" title="It opens in new window">CrossRef
7. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005;24:7435鈥?2. 38/sj.onc.1209097" target="_blank" title="It opens in new window">CrossRef
8. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabr貌 L, Cascinelli N, et al. Future perspectives in melanoma research. Meeting report from the 鈥淢elanoma Bridge. Napoli, December 2nd-4th 2012鈥? J Transl Med. 2013;11:137. 37" target="_blank" title="It opens in new window">CrossRef
9. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014;4:94鈥?09. 3-0617" target="_blank" title="It opens in new window">CrossRef
10. Hartsough E, Shao Y, Aplin AE. Resistance to RAF inhibitors revisited. J Invest Dermatol. 2014;134:319鈥?5. 38/jid.2013.358" target="_blank" title="It opens in new window">CrossRef
11. Slominski AT, Carlson JA. Melanoma resistance: a bright future for academicians and a challenge for patient advocates. Mayo Clin Proc. 2014;89:429鈥?3. CrossRef
12. Slominski A, Kim TK, Bro偶yna AA, Janjetovic Z, Brooks DL, Schwab LP, et al. The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1伪 expression and HIF-dependent attendant pathways. Arch Biochem Biophys. 2014;563:79鈥?3. 30" target="_blank" title="It opens in new window">CrossRef
13. Slominski A, Zmijewski MA, Pawelek J. L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res. 2012;25:14鈥?7. CrossRef
14. Chen J, Shen Q, Labow M, Gaither LA. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Cancer Res. 2011;71:4280鈥?1. 3761" target="_blank" title="It opens in new window">CrossRef
15. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065鈥?4.
16. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012;18:2316鈥?5. 32.CCR-11-2381" target="_blank" title="It opens in new window">CrossRef
17. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos Jr R, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19:657鈥?7. 32.CCR-11-1446" target="_blank" title="It opens in new window">CrossRef
18. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 2008;68:3429鈥?9. CrossRef
19. Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 2008;68:7638鈥?9. CrossRef
20. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11:909鈥?0. 35-7163.MCT-11-0989" target="_blank" title="It opens in new window">CrossRef
21. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2012;31:446鈥?7. 38/onc.2011.250" target="_blank" title="It opens in new window">CrossRef
22. Carli P, De Giorgi V, Chiarugi A, Stante M, Giannotti B. Multiple synchronous cutaneous melanomas: implications for prevention. Int J Dermatol. 2002;41:583鈥?. 365-4362.2002.01605.x" target="_blank" title="It opens in new window">CrossRef
23. Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA, Bianchi-Scarr脿 G, et al. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility. J Clin Oncol. 2004;22:286鈥?2. CrossRef
24. Palomba G, Colombino M, Contu A, Massidda B, Baldino G, Pazzola A, et al. Prevalence of / KRAS, / BRAF, and / PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med. 2012;10:178. CrossRef
25. Manca A, Sini MC, Izzo F, Ascierto PA, Tatangelo F, Botti G, et al. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol Rep. 2011;25:1495鈥?02.
26. Casula C, Muggiano A, Cossu A, Budroni M, Carac貌 C, Ascierto PA, et al. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer. 2009;9:352. 352" target="_blank" title="It opens in new window">CrossRef
27. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. / BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522鈥?. CrossRef
28. Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, et al. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med. 2013;11:202. CrossRef
29. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010;70:8736鈥?7. CrossRef
30. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71:2750鈥?0. CrossRef
31. Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, et al. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wild-type PTEN status. Mol Cancer. 2012;11:75. CrossRef
32. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 2012;25:248鈥?8. CrossRef
33. Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget. 2014;5:10206鈥?1.
34. Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol. 2006;126:1660鈥?. 38/sj.jid.5700311" target="_blank" title="It opens in new window">CrossRef
35. Omholt K, Kr枚ckel D, Ringborg U, Hansson J. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res. 2006;16:197鈥?00. 3" target="_blank" title="It opens in new window">CrossRef
36. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251鈥?3. CrossRef
37. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44:1006鈥?4. 38/ng.2359" target="_blank" title="It opens in new window">CrossRef
38. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015;135:508鈥?5. 38/jid.2014.366" target="_blank" title="It opens in new window">CrossRef
39. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008;99:1265鈥?. 38/sj.bjc.6604637" target="_blank" title="It opens in new window">CrossRef
40. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012;26:1055鈥?9. CrossRef
41. Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 2010;29:6222鈥?2. 38/onc.2010.349" target="_blank" title="It opens in new window">CrossRef
42. Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, et al. Whole genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol. 2014;25:959鈥?7. 3/annonc/mdu049" target="_blank" title="It opens in new window">CrossRef - 刊物主题：Biomedicine general; Medicine/Public Health, general;
- 出版者：BioMed Central
- ISSN：1479-5876
文摘
Background Activated PI3K-AKT pathway may contribute to decrease sensitivity to inhibitors of key pathogenetic effectors (mutated BRAF, active NRAS or MEK) in melanoma. Functional alterations are deeply involved in PI3K-AKT activation, with a minimal role reported for mutations in PIK3CA, the catalytic subunit of the PI3K gene. We here assessed the prevalence of the coexistence of BRAF/NRAS and PIK3CA mutations in a series of melanoma samples. Methods A total of 245 tumor specimens (212 primary melanomas and 33 melanoma cell lines) was screened for mutations in BRAF, NRAS, and PIK3CA genes by automated direct sequencing. Results Overall, 110 (44.9%) samples carried mutations in BRAF, 26 (10.6%) in NRAS, and 24 (9.8%) in PIK3CA. All identified PIK3CA mutations have been reported to induce PI3K activation; those detected in cultured melanomas were investigated for their interference with the antiproliferative activity of the BRAF-mutant inhibitor vemurafenib. A reduced suppression in cell growth was observed in treated cells carrying both BRAF and PIK3CA mutations as compared with those presenting a mutated BRAF only. Among the analysed melanomas, 12/245 (4.9%) samples presented the coexistence of PIK3CA and BRAF/NRAS mutations. Conclusions Our study further suggests that PIK3CA mutations account for a small fraction of PI3K pathway activation and have a limited impact in interfering with the BRAF/NRAS-driven growth in melanoma.